Cascadian Therapeutics, Inc. (CASC) Stock Rating Reaffirmed by Cantor Fitzgerald
Cascadian Therapeutics, Inc. (NASDAQ:CASC)‘s stock had its “hold” rating reiterated by investment analysts at Cantor Fitzgerald in a note issued to investors on Thursday. They presently have a $4.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 10.80% from the stock’s current price.
A number of other research firms have also commented on CASC. Cowen and Company reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a research note on Tuesday, May 9th. ValuEngine lowered shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research lowered shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $6.17.
Cascadian Therapeutics (NASDAQ CASC) opened at 3.61 on Thursday. The firm’s market capitalization is $182.50 million. The firm has a 50-day moving average price of $3.83 and a 200 day moving average price of $3.96. Cascadian Therapeutics has a one year low of $3.18 and a one year high of $10.98.
Cascadian Therapeutics (NASDAQ:CASC) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. During the same quarter last year, the business posted ($1.57) earnings per share. Equities research analysts anticipate that Cascadian Therapeutics will post $5.02 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Cascadian Therapeutics, Inc. (CASC) Stock Rating Reaffirmed by Cantor Fitzgerald” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/02/cascadian-therapeutics-inc-casc-stock-rating-reaffirmed-by-cantor-fitzgerald.html.
A number of institutional investors have recently bought and sold shares of CASC. NEA Management Company LLC raised its position in Cascadian Therapeutics by 405.9% in the first quarter. NEA Management Company LLC now owns 9,064,575 shares of the biopharmaceutical company’s stock worth $37,527,000 after buying an additional 7,272,909 shares in the last quarter. Baupost Group LLC MA raised its position in Cascadian Therapeutics by 109.3% in the first quarter. Baupost Group LLC MA now owns 8,721,079 shares of the biopharmaceutical company’s stock worth $36,105,000 after buying an additional 4,554,413 shares in the last quarter. Redmile Group LLC purchased a new position in Cascadian Therapeutics during the first quarter worth approximately $16,860,000. Vanguard Group Inc. raised its position in Cascadian Therapeutics by 24.1% in the second quarter. Vanguard Group Inc. now owns 1,767,681 shares of the biopharmaceutical company’s stock worth $6,567,000 after buying an additional 343,838 shares in the last quarter. Finally, Sandia Holdings LLC raised its position in Cascadian Therapeutics by 70.5% in the second quarter. Sandia Holdings LLC now owns 927,264 shares of the biopharmaceutical company’s stock worth $3,445,000 after buying an additional 383,545 shares in the last quarter. 82.55% of the stock is owned by hedge funds and other institutional investors.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Stock Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related stocks with our FREE daily email newsletter.